Drug Trial Radar · NCT00303784
Prostate Adenocarcinoma TransCutaneous Hormones
Last checked: Nov 20, 2026Latest source record: Nov 27, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
2,200
Planned (sponsor's estimate)
Start
Mar 2006
Primary completion
Aug 2021
Study completion Aug 2021
Sponsor
- Lead sponsor
- University College, LondonAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Medical Research Council
- First posted
- Mar 17, 2006
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Male only, up to 120 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
RATIONALE: The increasingly prolonged and extended use of androgen deprivation therapy (ADT) in the treatment of prostate cancer, usually achieved through the administration of LHRH agonists, has raised concerns about long-term toxicities, in particular osteoporosis and adverse metabolic changes which may be associated with type II diabetes and increased cardiovascular risk. An alternative approach is to investigate other methods of ADT. Oral oestrogen has been shown to be as effective as LHRH and surgical orchidectomy in achieving castrate levels of testosterone and has equivalent or improved prostate cancer outcomes but is not used routinely as first-line therapy because of the risk of cardiovascular system (CVS) complications. The CVS complications have been attributed to first-pass hepatic metabolism. Administering oestrogen parenterally avoids the entero-hepatic circulation and so is expected to mitigate the risk of CVS toxicity whilst still effectively suppressing testosterone to castrate levels. This hypothesis has been supported by results from the early stages of this trial which have provided sufficient indication of the safety and efficacy of the patches to warrant further investigation of the treatment in this setting, as recommended by the IDMC.. PURPOSE: This randomized phase III trial is studying how well the estrogen skin patch works compared with luteinizing hormone-releasing hormone agonist injections in treating patients with locally advanced or metastatic prostate cancer.
Conditions
- Anemia
- Cardiovascular Complications
- Hot Flashes
- Osteoporosis
- Prostate Cancer
Interventions
GoserelinDrug
3.6mg implant, in pre-filled syringe
EstradiolDrug
Each patch contains 3 mg of estradiol hemihydrate in a patch size of 30 cm2, releasing 100 micrograms of estradiol per 24 hours.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-Free SurvivalTime frame: Up to 180 months
- Overall SurvivalTime frame: Up to 180 months
Locations
32 sites in 1 country. Site status is shown where the registry gives one.
Queen's Hospital
Burton-on-Trent, England, United Kingdom · Recruiting
Addenbrooke's Hospital
Cambridge, England, United Kingdom · Recruiting
Walsgrave Hospital
Coventry, England, United Kingdom · Recruiting
Mid Cheshire Hospitals Trust- Leighton Hopsital
Crewe, England, United Kingdom · Recruiting
Mayday University Hospital
Croydon, England, United Kingdom · Recruiting
Derbyshire Royal Infirmary
Derby, England, United Kingdom · Recruiting
Castle Hill Hospital
East Yorkshire, England, United Kingdom · Recruiting
Royal Devon and Exeter Hospital
Exeter, England, United Kingdom · Recruiting
Grantham and District Hospital
Grantham, Lincolnshire, England, United Kingdom · Recruiting
Ipswich Hospital
Ipswich, England, United Kingdom · Recruiting
Kidderminster Hospital
Kidderminster Worcestershire, England, United Kingdom · Recruiting
Leeds Cancer Centre at St. James's University Hospital
Leeds, England, United Kingdom · Recruiting
St. Mary's Hospital
London, England, United Kingdom · Recruiting
Charing Cross Hospital
London, England, United Kingdom · Recruiting
Maidstone Hospital
Maidstone, England, United Kingdom · Recruiting
James Cook University Hospital
Middlesbrough, England, United Kingdom · Recruiting
Nottingham City Hospital
Nottingham, England, United Kingdom · Recruiting
Kings Mill Hospital
Nottinghamshire, England, United Kingdom · Recruiting
George Eliot Hospital
Nuneaton, England, United Kingdom · Recruiting
Alexandra Healthcare NHS
Redditch, Worcestershire, England, United Kingdom · Recruiting
Hope Hospital
Salford, England, United Kingdom · Recruiting
Scarborough General Hospital
Scarborough, England, United Kingdom · Recruiting
Stepping Hill Hospital
Stockport, England, United Kingdom · Recruiting
Hillingdon Hospital
Uxbridge, England, United Kingdom · Recruiting
Walsall Manor Hospital
Walsall, England, United Kingdom · Recruiting
Warwick Hospital
Warwick, England, United Kingdom · Recruiting
Worthing Hospital
Worthing, England, United Kingdom · Recruiting
Yeovil District Hospital
Yeovil, England, United Kingdom · Recruiting
Ayr Hospital
Ayr, Scotland, United Kingdom · Recruiting
Beatson West of Scotland Cancer Centre
Glasgow, Scotland, United Kingdom · Recruiting
Velindre Cancer Center at Velindre Hospital
Cardiff, Wales, United Kingdom · Recruiting
University Hospital of Wales
Cardiff, Wales, United Kingdom · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.